Zurich, Switzerland
MetrioPharm, founded in 2007, is a Swiss biotech innovator positioned "At the Forefront of Macrophage Metabolic Modulation." This company identifies a unique niche in immune modulation by targeting dysregulated mitochondrial metabolism in macrophages.
With its headquarters in Zurich and an R&D subsidiary in Berlin, MetrioPharm has developed a platform of oral small molecules, showcasing efficacy through three Phase II trials in treating inflammatory and infectious diseases, all while maintaining an excellent safety profile. Its lead candidate, MP1032, offers therapeutic benefits akin to corticosteroids but without the related serious side effects.
Moreover, MP1032 has demonstrated unique potential in combination therapies, allowing for reduced dosing of corticosteroids by up to 90%, positioning it as a potential groundbreaking advancement in corticosteroid-sparing therapies—an area stagnant for over six decades. The preclinical success noted in its antiviral and antibacterial properties enhances the compound's therapeutic appeal.
The most recent funding injection was received on 12 October 2022, amounting to €125.00K through a grant from Duchenne UK. Investors looking for pioneering developments in biotech, with promising clinical and preclinical results, would find MetrioPharm an intriguing opportunity.
